News

The future of good evidence gathering for PCa

New approaches to clinical trials can lead to more successful results in the challenging near future. Parallel, comparative studies and a better selection of patients are just some positive developments in the generation of useful evidence for prostate cancer...
EMUC_chairs

PCa management essentials opens EMUC’s 10th year

Throughout a decade, the European Multidisciplinary Congress on Urological Cancers (EMUC) has established its reputation as the leading platform where multidisciplinary specialists with expertise in urological malignancies come together. This year, EMUC commences in Amsterdam, The Netherlands. The programme...

Birtle to present key POUT findings and updates at EMUC18

The PeriOperative chemotheraphy or sUrveillance in upper Tract urothelial cancer, also known as POUT (CRUK/11/027; NCT01993979, NIHR portfolio) is the largest clinical trial in upper tract urothelial cancer (UTUC) with findings supporting the use of adjuvant platinum based chemotherapy...
Epstein EMUC

EMUC18: Everything in prostate cancer pathology you were afraid to ask

Marking its 10th year, this year’s annual European Multidisciplinary Congress on Urological Cancers (EMUC18) will emphasise the synergies from multidisciplinary teamwork (MDT) to highlight that comprehensive cancer care is only possible when various experts work together to identify and...

EMUC18: Joint initiatives reinforce effective MDT in onco-urology

Multidisciplinary teamwork, although a widely-accepted practice in medicine, still has a long way to go in actual clinical and research work considering new challenges encountered by physicians such as the introduction of new diagnostic and treatment agents and their...

EMUC18: Costs and optimal PCa care- Finding the crucial balance

Across Europe the debate has begun on how to deliver uniform and quality care for prostate cancer (PCa) patients in the region, but healthcare experts and physicians are encountering deeply-rooted issues that range from financial costs, poor patient recruitment...